Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers
Conditions:   Colorectal Carcinoma;   Gastric Adenocarcinoma;   Esophageal and GEJ Adenocarcinoma;   Cholangiocarcinoma;   Gallbladder Carcinoma
Interventions:   Drug: tucatinib;   Drug: trastuzumab;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: fluorouracil
Sponsor:   Seattle Genetics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 13, 2020 / by / in
Comments